...
首页> 外文期刊>Current opinion in endocrinology, diabetes, and obesity >Low-dose and high-dose adrenocorticotropin testing: indications and shortcomings.
【24h】

Low-dose and high-dose adrenocorticotropin testing: indications and shortcomings.

机译:低剂量和高剂量肾上腺皮质激素测试:适应症和缺点。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE OF REVIEW: The 250 microg adrenocorticotropin test (high-dose test) is the most commonly used adrenal stimulation test, though the use of physiologic doses (1.0 microg or 0.5 microg/1.73 m) (low-dose test) has recently gained wider acceptance. These variants and the use of adrenocorticotropin test in the ICU, however, remain controversial. The validity of the low-dose test and the parameters for evaluation of high- and low-dose tests in different situations need reevaluation. RECENT FINDINGS: In the last few years, numerous studies have used the low-dose test as a single test following previous findings that it is more sensitive and accurate than the high-dose test. It is used mainly in secondary adrenal insufficiency and after treatment with therapeutic glucocorticosteroids to define hypothalamo-pituitary-adrenal suppression. Unless there is a very recent onset of disease, the results are interpreted by most researchers as diagnostic. The treatment of relative adrenal insufficiency, based on delta cortisol, has not yielded proof of correlation between this diagnosis and better prognosis with glucocorticoid treatment. SUMMARY: For interpretation of an adrenocorticotropin test, only peak - and not delta - cortisol should be used. The use of 240-300 mg of hydrocortisone daily in ICU patients, including septic shock, should be considered as pharmacologic, rather than as a replacement dose. Using the low-dose test for this purpose will lead to further misdiagnosis.
机译:审查目的:尽管最近生理剂量(1.0微克或0.5微克/1.73 m)(低剂量试验)的使用范围更广,但250微克的肾上腺皮质激素试验(大剂量试验)是最常用的肾上腺刺激试验验收。这些变体以及在ICU中使用促肾上腺皮质激素测试仍然存在争议。低剂量测试的有效性以及在不同情况下用于评估高剂量和低剂量测试的参数需要重新评估。最近的发现:在过去的几年中,根据先前的发现,低剂量测试比高剂量测试更灵敏和准确,许多研究已将低剂量测试用作单个测试。它主要用于继发性肾上腺功能不全以及经治疗性糖皮质激素治疗后定义下丘脑-垂体-肾上腺抑制。除非最近才发病,否则大多数研究人员将结果解释为诊断性的。基于糖皮质激素的相对肾上腺皮质功能不全的治疗尚未得到该糖皮质激素治疗与更好的预后之间的相关性证据。摘要:为了解释促肾上腺皮质激素测试,仅应使用峰值而非皮质醇。在ICU患者中,包括败血性休克,每天使用240-300 mg氢化可的松应被视为具有药理学意义,而不是替代剂量。为此目的使用小剂量检测将导致进一步的误诊。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号